How is an eGFR slope endpoint defined across a renal trial?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What can I legitimately conclude from this figure?

Answering this needs the eGFR entry criteria of the trial you are quoting, because renal trials enrol by kidney function and the results do not transfer across strata.

Renal risk in practice comes from volume depletion: persistent vomiting or diarrhoea during dose escalation reduces renal perfusion, and acute kidney injury reported in this class clusters around exactly those episodes.

To be exact about it, proteinuria reduction appears early, within months; the divergence in hard endpoints takes years. A trial short enough to see the first is too short to see the second.

Reports of acute kidney injury in pharmacovigilance databases for this class are heavily confounded by the gastrointestinal effects that precede them, which is a real association with an unsurprising mechanism.

Research-use compounds are not approved for human use, and unverified content makes any dose-related renal reasoning unfounded from the start.

Quote the eGFR entry band with any renal result, or the result does not travel.

Start by separating the acute haemodynamic effect from the long-term trajectory. They point in opposite directions over the first few weeks and that confuses a lot of readings.

Combination with other agents acting on the same haemodynamics changes the picture, and that interaction is a clinical question rather than a pharmacological curiosity.

Mechanically, FLOW randomised people with type 2 diabetes and chronic kidney disease to semaglutide and reported roughly a twenty-four per cent reduction in the primary kidney composite, which combined kidney failure, sustained large eGFR decline and death from kidney or cardiovascular causes.

The caveat is that kidney function is exactly the sort of thing that should not be managed from a forum. This is background, not guidance.

Albuminuria is the fast signal and the composite is the answer.

edited 14 Jul 2026 by Dr_Ingrid_Baumgartner — clarified the distinction between purity and content

The honest answer is that the class slows progression in diabetic kidney disease and that no trial has shown it reverses established damage.

The initial eGFR dip is on the order of one to three millilitres per minute per 1.73 square metres and recovers. Reading it as harm and stopping is the error the pattern is designed to catch you with.

Regulatory acceptance of eGFR slope as an endpoint rests on published meta-analyses linking slope to subsequent kidney failure across many trials and drug classes.

Nothing here is medical advice, and anyone with existing kidney disease has a genuinely different risk calculus that needs a clinician.

Cite FLOW for hard kidney endpoints, not a cardiovascular trial subgroup.

An early dip in estimated glomerular filtration rate followed by a slower long-run decline is a familiar pattern in renoprotective agents and is not the same thing as kidney injury.

Slope-based endpoints — the rate of eGFR decline in millilitres per minute per year — are increasingly used because they need fewer participants than event counts. They are legitimate and they are not events.

A surrogate that moves is encouraging. A surrogate that moves is also how several drug classes in other fields were shown to be useless.

If gastrointestinal effects are severe enough to affect fluid intake, that is the renal risk worth attending to.